Ausgabe 5/2010
Inhalt (23 Artikel)
Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice
Ornella Letari, Catherine Booth, Albino Bonazzi, Paolo Garofalo, Francesco Makovec, Lucio C. Rovati, Gianfranco Caselli
A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer
A. Sabharwal, P. G. Corrie, R. S. Midgley, C. Palmer, J. Brady, P. Mortimer, A. J. Watson, G. P. Margison, M. R. Middleton
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study
Salvatore Del Prete, Liliana Montella, Michele Caraglia, Luigi Maiorino, Gregorio Cennamo, Vincenzo Montesarchio, Guido Piai, Antonio Febbraro, Luciano Tarantino, Elena Capasso, Giovannella Palmieri, Rosario Guarrasi, Maddalena Bianco, Rosanna Mamone, Clementina Savastano, Agata Pisano, Bruno Vincenzi, Antonietta Sabia, Alberto D’Agostino, Vincenzo Faiola, Raffaele Addeo
A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group
M. M. Moore, M. Stockler, R. Lim, T. S. K. Mok, M. Millward, M. J. Boyer
Syl611, a novel semisynthetic taxane derivative, reverses multidrug resistance by p-glycoprotein inhibition and facilitating inward transmembrane action
Yi Zhang, Hongyan Li, Hongbo Wang, Fuqin Su, Runjiang Qu, Dali Yin, Jungui Dai, Yan Li, Xiaoguang Chen
A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer
Jalid Sehouli, Oumar Camara, Sven Mahner, Thomas Bauknecht, Werner Lichtenegger, Ingo Runnebaum, Katherine Look, Fritz Jaenicke, Guelten Oskay-Oezcelik
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
Scott Ackler, Michael J. Mitten, Kelly Foster, Anatol Oleksijew, Marion Refici, Stephen K. Tahir, Yu Xiao, Christin Tse, David J. Frost, Stephen W. Fesik, Saul H. Rosenberg, Steven W. Elmore, Alexander R. Shoemaker
Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo
Caroline D. Scatena, Jeffrey L. Kumer, Jennifer P. Arbitrario, Anthony R. Howlett, Rachael E. Hawtin, Judith A. Fox, Jeffrey A. Silverman
Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer
Jung Hye Kwon, Jung Han Kim, Jung-Ae Lee, Hyun Chun Shin, Hyo Jung Kim, Hun Ho Song, Joo Young Jung, Ho Young Kim, Dae Ro Choi, Hyeong Su Kim, Young-iee Park, Dae Young Zang
Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α
Sreenivasulu Chintala, Károly Tόth, Shousong Cao, Farukh A. Durrani, Mary M. Vaughan, Randy L. Jensen, Youcef M. Rustum
Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer
Kazuhiro Yanagihara, Kenichi Yoshimura, Miyuki Niimi, Hiroyasu Yasuda, Takahiko Sasaki, Takafumi Nishimura, Hiroshi Ishiguro, Shigemi Matsumoto, Toshiyuki Kitano, Masashi Kanai, Akiko Misawa, Harue Tada, Satoshi Teramukai, Tadashi Mio, Masanori Fukushima
A general process for the development of peptide-based immunoassays for monoclonal antibodies
Ana B. Sanchez, Tammy Nguyen, Rhanika Dema-Ala, Andrew C. Kummel, Thomas J. Kipps, Bradley T. Messmer
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors
Robert J. Morgan, Timothy Synold, Adam Mamelak, Dean Lim, Zaid Al-Kadhimi, Przemyslaw Twardowski, Lucille Leong, Warren Chow, Kim Margolin, Stephen Shibata, George Somlo, Yun Yen, Paul Frankel, James H. Doroshow
Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors
Yasuhito Fujisaka, Yasuhide Yamada, Noboru Yamamoto, Toshio Shimizu, Yutaka Fujiwara, Kazuhiko Yamada, Tomohide Tamura, Hiroyuki Watanabe, Yu-Nien Sun, Michael B. Bass, Mitsuo Seki
Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression
Dilip Jain, Nila Patel, Melanie Shelton, Alakananda Basu, Rouel Roque, Wolfram Siede
Down-regulation of lipids transporter ABCA1 increases the cytotoxicity of Nitidine
Hironori Iwasaki, Takafumi Okabe, Kensaku Takara, Yasuhiko Yoshida, Kaoru Hanashiro, Hirosuke Oku
Phase II study of pemetrexed in patients with advanced neuroendocrine tumors
Jennifer A. Chan, Andrew X. Zhu, Keith Stuart, Pankaj Bhargava, Craig C. Earle, Jeffrey W. Clark, Carolyn Casey, Eileen Regan, Matthew H. Kulke
Increased anticoagulant activity of warfarin used in combination with doxifluridine
Masaru Nakajima, Tomoo Genda, Mayu Suehira, Hiroki Satoh, Akiko Miki, Satoko Hori, Yasufumi Sawada
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors
Brian S. Choi, Dona B. Alberti, William R. Schelman, Jill M. Kolesar, James P. Thomas, Rebecca Marnocha, Jens C. Eickhoff, S. Percy Ivy, George Wilding, Kyle D. Holen
Antitumor effects of recombinant human Interleukin-6 on mouse bladder carcinoma through Fas-mediated apoptosis
Chuan-gang Li, Mo-lin Li, Xiao-hong Shu, Yong-ji Liu, Wen-sen Wu
A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer
Manabu Shiozawa, Makoto Akaike, Nobuhiro Sugano, Kazuhito Tsuchida, Naoto Yamamoto, Soichiro Morinaga
Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients
Franca Formelli, Elena Cavadini, Roberto Luksch, Alberto Garaventa, Valentina Appierto, Stefano Persiani
C6 ceramide potentiates curcumin-induced cell death and apoptosis in melanoma cell lines in vitro
Teng Yu, Jinchao Li, Hui Sun